Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge
Jennifer M. Polinski, Andrew R. Weckstein, Michael Batech, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e222959-e222959
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
Manish Dhawan, Abhilasha Sharma, Priyanka Choudhary, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 87
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Katherine McMahan, Frank Wegmann, Malika Aïd, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 385-391
Open Access | Times Cited: 40
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Karin Hardt, An Vandebosch, Jerald Sadoff, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1703-1715
Open Access | Times Cited: 63
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Chen Tan, Ai‐ris Y. Collier, Jingyou Yu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2226335-e2226335
Open Access | Times Cited: 55
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
Nicholas Kim Huat Khoo, Joey Ming Er Lim, Upkar S. Gill, et al.
Med (2022) Vol. 3, Iss. 2, pp. 104-118.e4
Open Access | Times Cited: 51
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
June Young Chun, Hwichang Jeong, Yongdai Kim
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 30
COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19
Andrew Kemerley, Abhishek Gupta, Mahesh Thirunavukkarasu, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 3, pp. 1904-1920
Open Access | Times Cited: 5
Balancing fairness and efficiency in dynamic vaccine allocation during major infectious disease outbreaks
Zhaoli Dai, Hongjie Lan, Hai Nan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: an id.DRIVE test-negative case-control study
Chloé Wyndham-Thomas, E. Claire Newbern, Ainara Mira‐Iglesias, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 5, pp. 102700-102700
Open Access
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Zhongjie Sun, Tingxin Wu, Huangfan Xie, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 24
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice
Dimitrina Miteva, Meglena Kitanova, Hristiana Batselova, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1181-1181
Open Access | Times Cited: 13
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
Katherine E. Mues, Brenna Kirk, Deesha Patel, et al.
Vaccine (2022) Vol. 40, Iss. 47, pp. 6730-6739
Open Access | Times Cited: 17
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines
Joanna Szczepanek, Monika Skorupa, Agnieszka Goroncy, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 99-99
Open Access | Times Cited: 16
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine
Mathieu Le Gars, Jenny Hendriks, Jerald Sadoff, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 47-60
Open Access | Times Cited: 16
COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021–2022
Duncan Chanda, Jonas Z. Hines, Megumi Itoh, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 16
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
Ebuwa Igho-Osagie, Amy Puenpatom, Marissa Grifasi Williams, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 5, pp. 509-518
Open Access | Times Cited: 8
Prevalence of Diagnosed Genital Herpes and Antiviral Treatment in the United States
Purva Jain, Alan Embry, Brent Arakaki, et al.
Sexually Transmitted Diseases (2024) Vol. 51, Iss. 10, pp. 686-693
Closed Access | Times Cited: 2
Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017–2019
Deesha Patel, Zachary A. Marcum, Aisara Chansakul, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top